Background
Methods
Study design
Study population
MRI analyses
Endpoint definitions
Power calculation
Statistical analysis
Ethics
Results
Variable | Not closed (n = 86) | Closed (n = 101) | |
---|---|---|---|
Age – years | 69.3 ± 8.8 | 67.6 ± 9.6 | |
Men - n (%) | 75 (87.2) | 84 (83.2) | |
Clinical characteristics | |||
Congestive heart failure - n (%) | 15 (17.9) | 16 (15.8) | |
Atrial fibrillation - n (%) | 12 (12.8) | 18 (16.8) | |
Diabetes - n (%) | 19 (22.1) | 31 (30.7) | |
Hypertension - n (%) | 60 (69.8) | 75 (74.3) | |
CHADS-VASc – unit | 2.9 ± 1.4 | 2.9 ± 1.5 | |
Prior stroke - n (%) | 15 (17.4) | 11 (10.9) | |
Chronic kidney diseasea - n (%) | 14 (16.3) | 15 (14.9) | |
Medicine | |||
ASA - n (%) | 69 (80.2) | 75 (74.3) | |
Clopidogrel - n (%) | 14 (16.3) | 19 (18.8) | |
OAC | |||
VKA - n (%) | 26 (30.2) | 36 (35.6) | |
NOAC - n (%) | 2 (2.2) | 2 (2.0) | |
Beta-blocker - n (%) | 47 (54.7) | 61 (60.4) | |
Verapamil - n (%) | 4 (4.5) | 2 (2.0) | |
Calcium-blocker - n (%) | 19 (21.3) | 34 (33.7) | |
Digoxin - n (%) | 5 (5.6) | 3 (3.0) | |
Renin-angiotensin system blocker - n (%) | 40 (46.5) | 54 (53.5) | |
Amiodarone - n (%) | 23 (26.7) | 18 (17.8) | |
Statin - n (%) | 74 (86.0) | 81 (80.2) | |
Procedural characteristics | |||
Surgery type | |||
AVR only - n (%) | 17 (19.1) | 17 (16.8) | |
AVR with CABG - n (%) | 20 (22.5) | 22 (21.8) | |
AVR with aortic surgery - n (%) | 1 (1.1) | 1 (1.0) | |
AVR with MVR - n (%) | 0 (0) | 2 (2.0) | |
Aortic surgery only - n (%) | 1 (1.1) | 0 (0) | |
CABG only - n (%) | 40 (46.5) | 50 (49.5) | |
CABG with MVR - n (%) | 2 (2.3) | 2 (2.0) | |
MVR only - n (%) | 4 (4.5) | 7 (6.9) | |
Tricuspid surgery only - n (%) | 1 (1.2) | 0 (0) | |
Perioperative atrial fibrillation - n (%) | 52 (60.5) | 50 (50.0) |
Clinical outcomes
Endpoint | Not closed (n = 86) | Closed (n = 101) | Hazard ratio | P-value |
---|---|---|---|---|
Primary eventsa | 14 (16.3%) | 5 (5.0%) | 0.3 [95% CI: 0.1–0.8] | 0.0168 |
Clinical strokeb | 8 (10.0%) | 3 (3.0) | 0.3 [95% CI: 0.1–1.1] | 0.0763 |
Death | 12 (14.0%) | 12 (11.9%) | 0.8 [95% CI: 0.43–1.9] | 0.6562 |
Endpoint | Not closed (n = 77) | Closed (n = 64) | Hazard ratio | P-value |
---|---|---|---|---|
Primary eventsa | 14 (18.2%) | 4 (6.3%) | 0.3 [95% CI: 0.1–0.9] | 0.0237 |
Clinical strokeb | 8 (11.3%) | 2 (3.2%) | 0.3 [95% CI: 0.1–1.3] | 0.0907 |
Death | 10 (13.0%) | 6 (9.4%) | 0.7 [95% CI: 0.3–2.3] | 0.7067 |